Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.62 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.62 |
| ▸ | CES1 | P23141 | 4/20 | 0.61 |
| ▸ | FAAH | O00519 | 4/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.59 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19149704 | 1.00 | MAPT (0.71) | MAPTRXFP1ALDH1A1ALOX5HDAC1 | |
| SCHEMBL547835 | 1.00 | MAPT (0.71) | MAPTRXFP1ALDH1A1ALOX5HDAC1 | |
| SCHEMBL12040622 | 1.00 | MAPT (0.71) | MAPTRXFP1ALDH1A1ALOX5HDAC1 | |
| SCHEMBL8104136 | 1.00 | MAPT (0.71) | MAPTRXFP1ALDH1A1ALOX5HDAC1 | |
| SCHEMBL5681573 | 1.00 | MAPT (0.71) | MAPTRXFP1ALDH1A1ALOX5HDAC1 | |
| SCHEMBL6213668 | 1.00 | MAPT (0.71) | MAPTRXFP1ALDH1A1ALOX5HDAC1 | |
| SCHEMBL24340640 | 1.00 | MAPT (0.71) | MAPTRXFP1ALDH1A1ALOX5HDAC1 | |
| SCHEMBL13498521 | 1.00 | MAPT (0.71) | MAPTRXFP1ALDH1A1ALOX5HDAC1 | |
| SCHEMBL1105483 | 0.98 | ALDH1A1 (0.73) | MAPTRXFP1ALDH1A1ALOX5HDAC1 | |
| Formaldehyde SCHEMBL6456543 | 0.94 | ALDH1A1 (0.68) | MAPTRXFP1ALDH1A1ALOX5HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070287699-A1 | ANTIVIRAL AGENTS | VIROBAY, INC. (US) | 2007-12-13 | — | — | US | claimed |
| CN-112218844-B | Compound, resin, composition, resist pattern forming method, circuit pattern forming method, and resin purifying method | 三菱瓦斯化学株式会社 | 2024-04-26 | — | — | CN | disclosed |
| CN-115968391-B | Composition, resin, method for producing amorphous film, method for forming resist pattern, method for producing underlayer film for lithography, and method for forming circuit pattern | 三菱瓦斯化学株式会社 | 2024-04-26 | — | — | CN | disclosed |
| CN-111655662-B | Compound, resin, composition, resist pattern forming method, circuit pattern forming method, and resin purifying method | 三菱瓦斯化学株式会社 | 2023-09-26 | — | — | CN | disclosed |
| CN-116710500-A | Polymer, composition, method for producing polymer, composition for forming film, resist composition, method for forming resist pattern, radiation-sensitive composition, composition for forming underlayer film for lithography, method for producing underlayer film for lithography, method for forming circuit pattern, and composition for forming optical member | 三菱瓦斯化学株式会社 | 2023-09-05 | — | — | CN | disclosed |
| CN-116529671-A | Polycyclic polyphenol resin, composition, method for producing polycyclic polyphenol resin, composition for film formation, resist composition, method for forming resist pattern, radiation-sensitive composition, composition for forming underlayer film for lithography, method for producing underlayer film for lithography, method for forming circuit pattern, and composition for forming optical member | 三菱瓦斯化学株式会社 | 2023-08-01 | — | — | CN | disclosed |
| CN-116194502-A | Polymer, composition, method for producing polymer, composition, film-forming composition, resist composition, radiation-sensitive composition, underlayer film-forming composition for lithography, resist pattern-forming method, method for producing underlayer film for lithography, circuit pattern-forming method, and composition for forming optical member | 三菱瓦斯化学株式会社 | 2023-05-30 | — | — | CN | disclosed |
| CN-115968391-A | Composition, resin, method for producing amorphous film, method for forming resist pattern, method for producing underlayer film for lithography, and method for forming circuit pattern | 三菱瓦斯化学株式会社 | 2023-04-14 | — | — | CN | disclosed |
| CN-113365967-A | Compound, resin, composition, resist pattern forming method, circuit pattern forming method, and resin purifying method | 三菱瓦斯化学株式会社 | 2021-09-07 | — | — | CN | disclosed |
| CN-113302223-A | Film-forming composition, resist composition, radiation-sensitive composition, method for producing amorphous film, method for forming resist pattern, composition for forming underlayer film for lithography, method for producing underlayer film for lithography, and method for forming circuit pattern | 三菱瓦斯化学株式会社 | 2021-08-24 | — | — | CN | disclosed |
| US-20120101026-A1 | Compounds For Enzyme Inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| EP-2260835-A2 | Composition for proteasome inhibition | Proteolix, Inc. (US) | 2010-12-15 | — | — | EP | disclosed |
| EP-2261236-A2 | Composition for proteasome inhibition | Proteolix, Inc. (US) | 2010-12-15 | — | — | EP | disclosed |
| US-7737112-B2 | Composition for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-20090239891-A1 | Sustained Release Dosage Forms of Analgesic Medications | UNVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2009-09-24 | — | — | US | disclosed |
| US-20080090785-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20070287699-A1 | ANTIVIRAL AGENTS | VIROBAY, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| WO-2007103185-A2 | SUSTAINED RELEASE DOSAGE FORMS OF ANALAGESIC MEDICATIONS | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2007-09-13 | — | — | WO | disclosed |
| EP-1118629-B1 | Polyhydroxyalkanoates and method of producing them by utilizing microorganisms | CANON KK (JP) | 2007-04-25 | — | — | EP | disclosed |
| WO-2006063154-A1 | COMPOSITION FOR PROTEASOME INHIBITION | PROTEOLIX, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090785-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | ANPEP, DNPEP, CPN1 | MAPT 4108/4885RXFP1 3005/4885ALDH1A1 3376/4885 |
| US-20120101026-A1 | Compounds For Enzyme Inhibition | ANPEP, DNPEP, CPN1 | MAPT 3999/4885RXFP1 3467/4885ALDH1A1 3059/4885 |
| US-20070287699-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | MAPT 4635/4885RXFP1 4526/4885ALDH1A1 1759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.